MXPA04005343A - 4-fenil-tetrahidro-isoquinolinas sustituidas, procedimiento para su preparacion, su uso como medicamento, y medicamento que las contiene. - Google Patents
4-fenil-tetrahidro-isoquinolinas sustituidas, procedimiento para su preparacion, su uso como medicamento, y medicamento que las contiene.Info
- Publication number
- MXPA04005343A MXPA04005343A MXPA04005343A MXPA04005343A MXPA04005343A MX PA04005343 A MXPA04005343 A MX PA04005343A MX PA04005343 A MXPA04005343 A MX PA04005343A MX PA04005343 A MXPA04005343 A MX PA04005343A MX PA04005343 A MXPA04005343 A MX PA04005343A
- Authority
- MX
- Mexico
- Prior art keywords
- medicaments
- compounds
- treatment
- phenyltetrahydroisoquinolines
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos de la formula I(Ver formula I)en los que desde R1 hasta R9 tienen los significados dados en las reivindicaciones, son excepcionalmente apropiados como agentes antihipertensivos, para reducir o prevenir lesiones inducidas por isquemias, como medicamentos para intervenciones quirurgicas para el tratamiento de isquemias del sistema nerviosos, del ictus y de un edema cerebral, de un choque, de una propulsion respiratoria perjudicada, para el tratamiento de los ronquidos, como laxante, como agente contra ectoparasitos, para prevenir la formacion de calculos biliares, como agentes anti-ateroescleroticos, como agentes contra complicaciones tardias de la diabetes, canceres, trastornos fibroticos, disfuncion endotelial, hipertrofias de organos e hiperplasias de organos; ellos son inhibidores del antiporter celular entre sodio y un proton; ellos influyen sobre las lipoproteinas del suero y por lo tanto se pueden usar para la profilaxis y para la regresion de lesiones ateroescleoticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10159714 | 2001-12-05 | ||
| PCT/EP2002/012990 WO2003048129A1 (de) | 2001-12-05 | 2002-11-20 | Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005343A true MXPA04005343A (es) | 2004-09-27 |
Family
ID=7708117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005343A MXPA04005343A (es) | 2001-12-05 | 2002-11-20 | 4-fenil-tetrahidro-isoquinolinas sustituidas, procedimiento para su preparacion, su uso como medicamento, y medicamento que las contiene. |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1453810B1 (es) |
| JP (1) | JP4510457B2 (es) |
| KR (1) | KR20050044724A (es) |
| CN (1) | CN100497314C (es) |
| AR (1) | AR037620A1 (es) |
| AT (1) | ATE425968T1 (es) |
| AU (1) | AU2002356689B2 (es) |
| BR (1) | BR0214753A (es) |
| CA (1) | CA2469385A1 (es) |
| CO (1) | CO5580748A2 (es) |
| DE (1) | DE50213372D1 (es) |
| DK (1) | DK1453810T3 (es) |
| EC (1) | ECSP045138A (es) |
| ES (1) | ES2324528T3 (es) |
| HK (1) | HK1072597A1 (es) |
| HR (1) | HRP20040507A2 (es) |
| HU (1) | HUP0600854A2 (es) |
| IL (1) | IL162316A0 (es) |
| MA (1) | MA27147A1 (es) |
| MX (1) | MXPA04005343A (es) |
| MY (1) | MY157371A (es) |
| NO (1) | NO326650B1 (es) |
| NZ (1) | NZ533322A (es) |
| OA (1) | OA12740A (es) |
| PE (1) | PE20030726A1 (es) |
| PL (1) | PL369313A1 (es) |
| PT (1) | PT1453810E (es) |
| RS (1) | RS48004A (es) |
| RU (1) | RU2298003C2 (es) |
| TN (1) | TNSN04100A1 (es) |
| TW (1) | TWI281860B (es) |
| UA (1) | UA77042C2 (es) |
| WO (1) | WO2003048129A1 (es) |
| ZA (1) | ZA200403711B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| DE102004046492A1 (de) * | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| DE102005001411A1 (de) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| CN101163693B (zh) | 2005-02-18 | 2013-03-06 | 阿斯利康(瑞典)有限公司 | 抗菌哌啶衍生物 |
| EP1861393A2 (en) * | 2005-03-04 | 2007-12-05 | AstraZeneca AB | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors |
| DE102005044817A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| DE102006012545A1 (de) | 2006-03-18 | 2007-09-27 | Sanofi-Aventis | Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| KR101683318B1 (ko) * | 2008-12-31 | 2016-12-07 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2018129556A1 (en) * | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
| KR102138391B1 (ko) * | 2012-08-21 | 2020-07-27 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법 |
| CA2909169A1 (en) | 2013-04-12 | 2014-10-16 | Ardelyx, Inc. | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| CN103788084A (zh) * | 2014-03-02 | 2014-05-14 | 湖南华腾制药有限公司 | 四氢异喹啉衍生物及其合成方法 |
| RU2703456C2 (ru) * | 2014-07-25 | 2019-10-17 | Тайсо Фармасьютикал Ко., Лтд. | Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом |
| JP6903923B2 (ja) * | 2016-01-22 | 2021-07-14 | 大正製薬株式会社 | ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬 |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
| EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
| TWI805137B (zh) * | 2020-12-18 | 2023-06-11 | 大陸商上海濟煜醫藥科技有限公司 | 苯并雜環取代四氫異喹啉類化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19951702A1 (de) * | 1999-10-27 | 2001-05-03 | Aventis Pharma Gmbh | Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten |
| CN1414953A (zh) * | 1999-11-03 | 2003-04-30 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5－羟色胺重摄取的用途 |
| JP4907817B2 (ja) * | 1999-11-03 | 2012-04-04 | エーエムアール テクノロジー インコーポレイテッド | ノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するための、４−フェニル置換テトラヒドロイソキノリン類およびその利用 |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| DE10019062A1 (de) * | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
-
2002
- 2002-11-20 RS YU48004A patent/RS48004A/sr unknown
- 2002-11-20 CA CA002469385A patent/CA2469385A1/en not_active Abandoned
- 2002-11-20 OA OA1200400166A patent/OA12740A/en unknown
- 2002-11-20 AU AU2002356689A patent/AU2002356689B2/en not_active Ceased
- 2002-11-20 JP JP2003549321A patent/JP4510457B2/ja not_active Expired - Fee Related
- 2002-11-20 NZ NZ533322A patent/NZ533322A/en unknown
- 2002-11-20 CN CNB028278879A patent/CN100497314C/zh not_active Expired - Fee Related
- 2002-11-20 BR BR0214753-0A patent/BR0214753A/pt not_active IP Right Cessation
- 2002-11-20 EP EP02804183A patent/EP1453810B1/de not_active Expired - Lifetime
- 2002-11-20 RU RU2004120295/04A patent/RU2298003C2/ru not_active IP Right Cessation
- 2002-11-20 PT PT02804183T patent/PT1453810E/pt unknown
- 2002-11-20 DE DE50213372T patent/DE50213372D1/de not_active Expired - Lifetime
- 2002-11-20 IL IL16231602A patent/IL162316A0/xx unknown
- 2002-11-20 ES ES02804183T patent/ES2324528T3/es not_active Expired - Lifetime
- 2002-11-20 MX MXPA04005343A patent/MXPA04005343A/es active IP Right Grant
- 2002-11-20 PL PL02369313A patent/PL369313A1/xx not_active Application Discontinuation
- 2002-11-20 DK DK02804183T patent/DK1453810T3/da active
- 2002-11-20 AT AT02804183T patent/ATE425968T1/de not_active IP Right Cessation
- 2002-11-20 HU HU0600854A patent/HUP0600854A2/hu unknown
- 2002-11-20 KR KR1020047008697A patent/KR20050044724A/ko active IP Right Grant
- 2002-11-20 WO PCT/EP2002/012990 patent/WO2003048129A1/de active Application Filing
- 2002-11-20 UA UA20040705310A patent/UA77042C2/uk unknown
- 2002-11-26 PE PE2002001138A patent/PE20030726A1/es not_active Application Discontinuation
- 2002-12-03 AR ARP020104667A patent/AR037620A1/es unknown
- 2002-12-03 TW TW091134977A patent/TWI281860B/zh not_active IP Right Cessation
- 2002-12-04 MY MYPI20024565A patent/MY157371A/en unknown
-
2004
- 2004-05-14 ZA ZA200403711A patent/ZA200403711B/en unknown
- 2004-05-21 MA MA27693A patent/MA27147A1/fr unknown
- 2004-05-25 NO NO20042158A patent/NO326650B1/no not_active IP Right Cessation
- 2004-06-03 CO CO04052088A patent/CO5580748A2/es not_active Application Discontinuation
- 2004-06-04 TN TNP2004000100A patent/TNSN04100A1/en unknown
- 2004-06-04 EC EC2004005138A patent/ECSP045138A/es unknown
- 2004-06-04 HR HR20040507A patent/HRP20040507A2/hr not_active Application Discontinuation
-
2005
- 2005-06-22 HK HK05105174.2A patent/HK1072597A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS48004A (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments,in addition to a medicament containing same | |
| BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| UA83182C2 (en) | Compounds effecting glucokinase | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| GB0318447D0 (en) | Therapeutic agents | |
| GB0112348D0 (en) | Compounds | |
| ATE190840T1 (de) | Zusammensetzung zur behandlung der parkinson- krankheit | |
| IL192106A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| WO2007023072A3 (en) | Use of ambroxol for the treatment of rhinovirus infections | |
| WO2001092218A3 (en) | Polyamine analogues as therapeutic and diagnostic agents | |
| ATE296802T1 (de) | Substituierte heterocyclo-norbornylamino-derivate,verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament | |
| NO20022801L (no) | Substituerte norbornylaminoderivater, fremgangsmåter for deres fremstilling, deres anvendelse som medikament ellerdiagnostikum såvel som medikamenter inneholdende disse | |
| CA2480429A1 (en) | Novel therapeutical use of agonist ligands specific to g2a receptor | |
| BR0312470A (pt) | Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto | |
| ATE325100T1 (de) | Substituierte 4-phenyltetrahydroisochinolinium- salze, verfahren zu ihrer herstellung, ihrer verwendung als medikament, sowie sie enthaltendes medikament | |
| BR0112609A (pt) | Derivados de anilina | |
| WO2007117272A3 (en) | Methods for treatment of hemorrhagic shock and related disorders | |
| PT1196170E (pt) | Utilizacao de um composto macrolido para a preparacao de um medicamento para o tratamento de lesoes cerebrais isquemicas ou hemorragicas | |
| TH48054A3 (th) | วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม | |
| WO2007131488A3 (de) | Verwendung von chinolonderivaten als anti-protozoäre mittel und in kombinatinonspräparaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status | ||
| FG | Grant or registration |